Safety and immunogenicity of diphtheria-tetanus-pertussis vaccine and hepatitis B vaccine as a new tetravalent combination (DTwP/HB) administered alone and at separate sites (DTwP and HB) including comparison with standard commercially available combination vaccine in Indian infants 6-14 weeks of age

Human Vaccines

Volumn 5, Issue 5, 2009, Pages 310-314

  Sharma, Hitt J ^a   Dutta, Ashok K ^b   Joshi, Surekha M ^c   Malik, Sushma ^c   Bhardwaj, Subodh ^a   Namjoshi, Gajanan S ^a   Parekh, Sameer S ^a  

^a Serum Institute of India Ltd   (India)

^b KALAWATI SARAN CHILDREN'S HOSPITAL   (India)

^c BYL NAIR CHARITABLE HOSPITAL   (India)

Author keywords

DTwP HB vaccine; Immunogenicity; Reactogenicity

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TATANUS PERTUSSIS HEPATITIS B VACCINE; GENEVAC B; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; Q VAC; TRITANRIX HB; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYING; DIPHTHERIA; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INDIAN; INFANT; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; PERTUSSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN REDNESS; TERTIARY HEALTH CARE; TETANUS; VACCINATION;

ANTIBODIES, BACTERIAL; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG TOXICITY; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNOGLOBULIN G; INDIA; INFANT; MALE; VACCINES, COMBINED;

EID: 70349553808     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.5.6909     Document Type: Article

References (26)

1. Kane MA, Clements J, Hu D. Hepatitis B Disease control priorities in developing countries. In: World Bank Book, New York: Oxford University Press, 1993; 321-30.
2. WHO position paper on hepatitis B Vaccine. Weekly Epidemiological Record 2004; 79:253-64.
3. Centers for Disease Control. Hepatitis B virus - a comprehensive strategy for eliminating transmission in the United States through Universal childhood vaccination, recommendation of the Immunization Practices Committee (ACIP) MMWR 1991; 40:1-20.
4. WHO Vaccine Preventable Disease Monitoring System 2007; Global Summary.
5. WHO 45th World Health Assembly. Expanded programme on immunization and vaccine quality. Progress report by the Director General 1992; 45-8.
6. WHO/UNICEF Global Immunization Coverage 2006.
7. Kane M. Global programme for control of Hepatitis B infection. Vaccine 1995; 13:547-9.
8. Diez-Delgado J, Dal-Re R, Llorente M, Gonzalez A, Lopez J. Hepatitis B component does not interfere with immune response to diphtheria, tetanus and whole cell Bordetella Pertussis components of a quadrivalent (DTwP HB) vaccine: A controlled trial in healthy infants. Vaccine 1997; 15:1418-22.
9. Introducing Hepatitis B vaccine into national immunization services. WHO Department of Vaccines and Biologicals 2001.
10. Prikazsky V, Bock HL. Higher anti-hepatitis B response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4 and 5 months of age in Slovakia. IJCP 2001; 55:3.
11. Usonis V, Bakasenas V, Taylor D, Vandepapeliere P. Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in lithuanian infants. Eur J Pediatr 1996; 144:189-93.
12. Poovorawan Y, Theamboonlers A, Sanpavat S, Chongsrisawat V, Willems P, Safary A. Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Asian Pac J Allergy Immunol 1999; 17:113-20.
13. Arestegui J, Garrote E, Gonzalez A, Arrate JP, Perez A, Vandepapelière P. Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4 and 6 months of age. Vaccine 1997; 15:7-9.
14. Decker M, Edwards K. Combination vaccines. In: Plotkin S, Orenstein W, eds. Vaccines, 3rd Edition. Philadelphia: W.B. Saunders Company 1998; 521-2.
15. Wassilak S, Orenstein W, Sutter R. Tetanus toxoid. In: Plotkin S, Orenstein W, eds. Vaccines, 3rd Edition. Philadelphia: W.B. Saunders Company 1998; 460.
16. Durate M, Oliveira M, Shikanai Yasuda, Mäkelä PH, Mäkelä O. Maternal antibodies partly inhibit an active antibody response to routine tetanus toxoid immunization in infants. J Infect Dis 1992; 165:977-9.
17. Osborn JJ, Dancis J, Julia F. Studies of the immunology of the new-born infant. Interference with active immunization by passive trans-placental circulating antibody. Pediatrics 1952; 10:328-34.
18. World Health Organization. Informal consultation on quadruvalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final report. WHO Geneva 1992; 1-12.
19. A report of committee to review the adverse consequences of pertussis and rubella vaccines. Christopher P, Cynthia J, Harvey V. (Editors). National Academy Press, Washington DC 1991.
20. Delgado JD, Dal-Re R, Llorente M, et al. Hepatitis B component does not interfere with the immune response to diphtheria, tetanus and whole cell Bordetella pertussis components of a quadruvalent DTPw-HB vaccine: A controlled in healthy infants. Vaccine 1997; 12:1418-22.
21. CPMP guidance on vaccine clinical studies. CPMP/EWP/463/97; 15/17; 1999.
22. WHO position paper on Diphtheria vaccine. Weekly Epidemiological Record 2006; 81:24-31.
23. WHO position paper on Tetanus vaccine. Weekly Epidemiological Record 2006; 81:198-207.
24. WHO position paper on Pertussis vaccine. Weekly Epidemiological Record 2005; 80:31-9.
25. WHO Technical Report Series No. 941, 2007. Annex 6. Recommendations for whole-cell pertussis vaccine.
26. Cohen JA. Power Primer Psychological Bulletin 112:155-9.